Medella Therapeutics Limited

University of Sheffield

Gareth Owain Richards

Timothy Michael Skerry

Karl Richard Gibson

Paul Alan Glossop

Roderick Alan Porter

Jean-Olivier Zirimwabagabo

Paul Matthew Blaney

Joseph P A Harrity

Matthew J Tozer

Joseph PA Harrity

Timothy M Skerry

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R, R, R, R, R, R, R, R, X, X, X, X, Land n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM). Also disclosed are the compounds for use in the treatment of diseases modulated AM, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds. 

Compounds

The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure may be used in the treatment of, for example, cancer, obesity and other disorders.

Therapeutic agent

The present invention provides an isolated antibody capable of binding a receptor activity modifying protein (RAMP) of CRLR receptor which antibody is of IgG, IgA or IgM isotype.

Antibodies against RAMP3

Growing community of inventors

Ellerstadt, United Kingdom

Gareth Owain Richards